Przejdź do zawartości
Merck

The mitochondria-targeted nitroxide JP4-039 augments potentially lethal irradiation damage repair.

In vivo (Athens, Greece) (2009-09-26)
Malolan S Rajagopalan, Kanika Gupta, Michael W Epperly, Darcy Franicola, Xichen Zhang, Hong Wang, Hong Zhao, Vladimir A Tyurin, Joshua G Pierce, Valerian E Kagan, Peter Wipf, Anthony J Kanai, Joel S Greenberger
ABSTRAKT

It was unknown if a mitochondria-targeted nitroxide (JP4-039) could augment potentially lethal damage repair (PLDR) of cells in quiescence. We evaluated 32D cl 3 murine hematopoietic progenitor cells which were irradiated and then either centrifuged to pellets (to simulate PLDR conditions) or left in exponential growth for 0, 24, 48 or 72 h. Pelleted cells demonstrated cell cycle arrest with a greater percentage in the G(1)-phase than did exponentially growing cells. Irradiation survival curves demonstrated a significant radiation damage mitigation effect of JP4-039 over untreated cells in cells pelleted for 24 h. No significant radiation mitigation was detected if drugs were added 48 or 72 h after irradiation. Electron paramagnetic resonance spectroscopy demonstrated a greater concentration of JP4-039 in mitochondria of 24 h-pelleted cells than in exponentially growing cells. These results establish a potential role of mitochondria-targeted nitroxide drugs as mitigators of radiation damage to quiescent cells including stem cells.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
JP4-039, ≥98% (HPLC)